|1.||Duesbery, Nicholas S: 6 articles (07/2012 - 01/2003)|
|2.||Frucht, David M: 5 articles (01/2012 - 05/2004)|
|3.||Fang, Hui: 5 articles (01/2012 - 05/2004)|
|4.||Leppla, Stephen H: 5 articles (01/2008 - 01/2003)|
|5.||Frankel, Arthur E: 4 articles (01/2008 - 01/2003)|
|6.||Garraway, Levi A: 3 articles (01/2014 - 05/2007)|
|7.||Bromberg-White, Jennifer L: 3 articles (07/2012 - 01/2008)|
|8.||Boyle, David L: 3 articles (03/2012 - 09/2003)|
|9.||Firestein, Gary S: 3 articles (03/2012 - 09/2003)|
|10.||Hammaker, Deepa: 3 articles (03/2012 - 09/2003)|
01/01/2012 - "Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclinical cancer models, leading to the initiation of clinical trials cotargeting these two key cancer signaling pathways. "
09/01/2009 - "The principal objective of this study was to improve our current understanding of drug interactions between EGFR and MAP/ERK kinase (MEK) inhibitors in an effort to gain insight into a novel therapeutic strategy against EGFR WT tumors. "
03/01/2015 - "ERK1/2, one of MAPK kinases, is expressed high in cervical cancer tissue. "
01/01/2015 - "CDH1 and IL1-beta expression dictates FAK and MAPKK-dependent cross-talk between cancer cells and human mesenchymal stem cells."
12/01/2014 - "Inhibition of MAP/ERK kinase (MEK) is a promising strategy to control the growth of tumors that are dependent on aberrant signaling in the MEK pathway. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/05/2010 - "Our aim was to investigate the prognostic and predictive value of the oncogenic MAPKK-like protein T-cell-originated protein kinase (TOPK) stratified by KRAS and BRAF mutations in patients with sporadic, hereditary and metastatic colorectal cancer (CRC) treated with anti-EGFR therapy. "
07/01/2007 - "However, the role of MAPK kinases (MAPKKs or MEKs) in cancer is unclear, although constitutively activated MEK1, which does not exist in nature, is "oncogenic." Herein, we found that T-cell-originated protein kinase (TOPK), a member of the MAPKK protein family, is highly expressed in human colorectal cancer tissues and cell lines and plays an important role in the transformation of colorectal cancer. "
11/15/2013 - "In this study, we tested the efficacy of a type 1 insulin-like growth factor receptor (IGF1R)/insulin receptor (IR) tyrosine kinase inhibitor, OSI-906, in combination with a mitogen-activated protein (MAP)-ERK kinase (MEK) 1/2 inhibitor based on evidence that the MAP kinase pathway was upregulated in colorectal cancer cell lines that were resistant to OSI-906. "
|3.||Melanoma (Melanoma, Malignant)
07/01/2013 - "Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. "
07/10/2006 - "Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAF(V600E)). "
05/01/2014 - "We hypothesized that combining vemurafenib with a MAP-ERK kinase (MEK) inhibitor would inhibit ERK activation in the melanoma and prevent ERK activation by vemurafenib in the leukemia, and thus suppress both malignancies. "
10/15/2013 - "The recent regulatory approval of RAF inhibitors and a MAP-ERK kinase (MEK) inhibitor for metastatic melanoma provides clinical validation of tumor dependency on this pathway. "
09/15/2003 - "We synthesized a previously characterized MAP kinase kinase inhibitor to test the effect that blocking the Ras-Raf-MAPK pathway would have on the establishment and maintenance of melanoma metastases. "
|4.||Breast Neoplasms (Breast Cancer)
07/15/2009 - "A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. "
08/01/2014 - "These results suggest that MEKS inhibits cell proliferation and induces apoptosis in breast cancer cells and that MEKS may have potential chemotherapeutic value for the treatment of human breast cancer."
12/14/2001 - "Using PR-transfected breast cancer cells MDA-MB-231, this report describes the similarities and differences between progesterone- and RU486-mediated effects on cell growth, cell differentiation and, at the molecular level, on the activation of p44/p42 MAP kinases (MAPK). "
08/01/2014 - "We examined the effects of MEKS on the proliferation rate, cell cycle arrest, reactive oxygen species (ROS) generation and activation of apoptosis-associated proteins in MDA-MB-231, human breast cancer cells. "
|2.||DNA (Deoxyribonucleic Acid)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Somatomedin Receptors (Somatomedin Receptor)
|6.||3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanol
|9.||Protein Kinases (Protein Kinase)
|1.||Molecular Targeted Therapy